Please ensure Javascript is enabled for purposes of website accessibility
Home / Products / Antibody / Polyclonal Antibody

Anti-Human TF/Transferrin Polyclonal Antibody

Catalog #:   PHC02101 Specific References (50) DATASHEET
Host species: Rabbit
Isotype: IgG
Applications: ELISA, IHC, WB
Accession: P02787
Overview

Catalog No.

PHC02101

Species reactivity

Human

Host species

Rabbit

Isotype

IgG

Clonality

Polyclonal

Immunogen

E. coli - derived recombinant Human TF (Thr24-Thr349).

Tested applications

ELISA: 1:4000-1:8000, IHC: 1:50-1:100, WB: 1:1000-1:4000

Target

Serotransferrin, Beta-1 metal-binding globulin, Siderophilin, Transferrin, TF

Purification

Purified by antigen affinity column.

Accession

P02787

Applications

ELISA, IHC, WB

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4, 50% Glycerol, 0.05% Proclin 300.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.

Data Image
  • Western Blot
    Various lysates were subjected to SDS PAGE followed by western blot with TF antibody (PHC02101) at 1μg/ml.

    Lane 1: Human plasma lysate

    Second Ab: Goat Anti-Rabbit IgG H&L Polyclonal antibody, HRP (PTB96431) at 0.1 μg/mL.

    Predict MW: 77 kDa
    Observed MW: 77 kDa
  • Immunohistochemical
    Immunohistochemical analysis of human ovarian cancer tissue stained for TF with PHC02101.
  • Western Blot
    Recombinant Protein lysates were subjected to SDS PAGE followed by western blot with TF/Transferrin antibody (PHC02101) at 1 µg/ml.

    Lane 1: Recombinant Protein

    Second Ab: Goat Anti-Rabbit IgG H&L Polyclonal antibody, HRP (PTB96431) at 0.1 μg/mL.

    Predict MW: 38 kDa
    Observed MW: 38 kDa
References

Mass cytometric detection of homologous recombination proficiency in circulating tumor cells to predict chemoresistance of metastatic breast cancer patients., PMID:40456663

Patritumab deruxtecan in leptomeningeal metastatic disease of solid tumors: the phase 2 TUXEDO-3 trial., PMID:40447851

The Effect of Fremanezumab on Pain in Patients with Complex Regional Pain Syndrome: Study Protocol of a Randomized, Double-Blind, Proof-of-Concept, Placebo-Controlled Trial., PMID:40426639

Correlation between tumor growth rate and survival in patients with metastatic breast cancer treated with trastuzumab deruxtecan., PMID:40349141

Targeting the HER2-ELF3-KRAS axis: a novel therapeutic strategy for KRASG13D colorectal cancer., PMID:40340861

Machine learning model for differentiating malignant from benign thyroid nodules based on the thyroid function data., PMID:40335136

Controlling reactogenicity while preserving immunogenicity from a self-amplifying RNA vaccine by modulating nucleocytoplasmic transport., PMID:40301369

Plasma Exchange vs. Immunoadsorption: Effects on Immunological Markers and Predictive Value in Steroid-Refractory MS Attacks., PMID:40292037

SARS-CoV-2 mRNA Vaccines Induce Cross-Reactive Antibodies to NL63 Coronavirus but Do Not Boost Pre-Existing Immunity Anti-NL63 Antibody Responses., PMID:40266143

Anti-β2glycoprotein I-induced neutrophil extracellular TRAPS cause endothelial activation., PMID:40238197

Multi-lineage transcriptional and cell communication signatures define pathways in individuals at-risk for developing rheumatoid arthritis that initiate and perpetuate disease., PMID:40235495

Protective Immunity of a Novel Multi-Epitope Vaccine Encoding OMP31, TF, BLS, SOD, BP26, and L9 Against Brucella spp. Infection., PMID:40223393

Bortezomib, melphalan, and prednisone with or without daratumumab in transplant-ineligible patients with newly diagnosed multiple myeloma (ALCYONE): final analysis of an open-label, randomised, multicentre, phase 3 trial., PMID:40220771

Concordance of BRAF V600E mutation between immunohistochemistry and genomic testing for thyroid cancer., PMID:40210835

Safety, tolerability, and pharmacokinetics of ASP1235 in relapsed or refractory acute myeloid leukemia: A phase 1 study., PMID:40209615

An updated compendium and reevaluation of the evidence for nuclear transcription factor occupancy over the mitochondrial genome., PMID:40163815

Guselkumab binding to CD64+ IL-23-producing myeloid cells enhances potency for neutralizing IL-23 signaling., PMID:40145093

TF-chRDP: a method for simultaneously capturing transcription factor binding chromatin-associated RNA, DNA and protein., PMID:40123855

Preclinical B cell depletion and safety profile of a brain-shuttled crystallizable fragment-silenced CD20 antibody., PMID:40118783

Immunoelectrochemical assessment of human IgE in non-invasive samples of allergic individuals using PdNCs-labelled antibodies., PMID:40100481

TNF signature in advanced melanoma patients treated with immune checkpoint inhibitors: Results from the MELANFα clinical study., PMID:40098565

Endothelial cell activation enhances thromboinflammation in vaccine-induced immune thrombotic thrombocytopenia., PMID:40085945

Evaluation of hyperprogressive disease with atezolizumab plus bevacizumab for hepatocellular carcinoma: A secondary analysis of the IMbrave150 trial., PMID:40079683

Simultaneous Isolation and Purification of Transferrin and Immunoglobulin G from Human Serum-A New Biotech Solution., PMID:40076217

F3 Expression Drives Sensitivity to the Antibody-Drug Conjugate Tisotumab Vedotin in Glioblastoma., PMID:40075681

Molecular determinants of response to neoadjuvant pembrolizumab plus chemotherapy in patients with high-risk, early-stage, triple-negative breast cancer: exploratory analysis of the open-label, multicohort phase 1b KEYNOTE-173 study., PMID:40069763

Prevalence of ocular Chlamydia trachomatis infection and antibodies within districts persistently endemic for trachoma, Amhara, Ethiopia., PMID:40067808

Comparative effectiveness of subcutaneous sarilumab 200 mg biweekly, subcutaneous Tocilizumab 162 mg biweekly, and intravenous Tocilizumab 8 mg/kg every 4 weeks in patients with rheumatoid arthritis: a prospective cohort study., PMID:40055759

Tissue Factor Pathway-Driven Initial Thrombin Generation is Associated with Hypercoagulability in Obesity., PMID:40049601

Matching-adjusted indirect comparison of efficacy and safety of lisocabtagene maraleucel and mosunetuzumab for the treatment of third-line or later relapsed or refractory follicular lymphoma., PMID:40045329

Daratumumab/lenalidomide/dexamethasone in transplant-ineligible newly diagnosed myeloma: MAIA long-term outcomes., PMID:40016302

Individual Genomic Loci, Transcript Level and Serum Profile of Immune, Antioxidant and Hormonal Markers Associated with Sheep Arthritis., PMID:40005882

Efficacy and safety of fasinumab in an NSAID-controlled study in patients with pain due to osteoarthritis of the knee or hip., PMID:40001000

Multi-lineage transcriptional and cell communication signatures define pathways in individuals at-risk for developing rheumatoid arthritis that initiate and perpetuate disease., PMID:39974976

Roadmap for alleviating the manifestations of ageing in the cardiovascular system., PMID:39972009

Stimulation of endothelin-1 production by autoantibodies present in patients with scleroderma renal crisis., PMID:39956166

Acupuncture for the prevention of episodic migraine., PMID:39932102

A comparison between adjuvant and delivering functions of iron oxide and calcium phosphate nanoparticles, using a model protein against Brucella melitensis., PMID:39927221

Advancing Optical Coherence Tomography Diagnostic Capabilities: Machine Learning Approaches to Detect Autoimmune Inflammatory Diseases., PMID:39910704

Characterization of Hospital Admissions During Immune Checkpoint Inhibitor Therapy: Insights From the ICOG Study., PMID:39865401

No correlation between thrombin generation and emicizumab levels: implications for monitoring emicizumab therapy., PMID:39850577

Daratumumab plus lenalidomide/dexamethasone in untreated multiple myeloma: analysis of key subgroups of the MAIA study., PMID:39815052

Rational selection of TbpB variants yields a bivalent vaccine with broad coverage against Neisseria gonorrhoeae., PMID:39814726

Single-cell mapping of regulatory DNA:Protein interactions., PMID:39803441

The real-world efficacy and safety of frontline therapy of obinutuzumab plus bendamustine for untreated high-tumor-burden follicular lymphoma., PMID:39776016

Virulence and Replicative Fitness of HIV-1 Transmitted/Founder (T/F) Viruses Harbouring Drug Resistance-Associated Mutation., PMID:39772167

Cardiovascular Safety and Fracture Prevention Effectiveness of Denosumab Versus Oral Bisphosphonates in Patients Receiving Dialysis : A Target Trial Emulation., PMID:39761590

Tissue factor targeted near-infrared photoimmunotherapy: a versatile therapeutic approach for malignancies., PMID:39751657

The spatially informed mFISHseq assay resolves biomarker discordance and predicts treatment response in breast cancer., PMID:39747865

Standardized workflow for multiplexed charge detection mass spectrometry on orbitrap analyzers., PMID:39747675

Datasheet
$ 170
Product specifications
50 μg 170 100 μg 280

Contact Information

Order: order@antibodysystem.com

Mail: support@antibodysystem.com

Distributor list

For research use only. Not for human or drug use.

Need help with your order?

Find out more about placing an order here

Anti-Human TF/Transferrin Polyclonal Antibody [PHC02101]
Terms of sale Website terms of use Cookie policy Privacy
Copyright © 2025 AntibodySystem SAS. All Rights Reserved.            All Products are for Research Use Only